ARQT News and Press, Arcutis Biotherapeutics Inc. From 07/31/20

Once-daily roflumilast demonstrated favorable safety and tolerability over 52 to 64 weeks of treatment At 52 to 64 weeks of treatment, 44% of subjects had attained an IGA of clear or almost clear Preliminary data further support the potential of roflumilast as a novel, once-daily, chron...

Arcutis Biotherapeutics ( ARQT +4.3% ) names Verrica Pharma's ( VRCA -2.8% ) Patrick Burnett as Chief Medical Officer (CMO) , effective August 1. More news on: Arcutis Biotherapeutics, Inc., Verrica Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move, Read more .....

Experienced industry leader to head Arcutis’ clinical development programs Appointment aligns with Arcutis’ strategy of building a team with deep dermatology expertise Howard Welgus, M.D., FAAD to retire; elected to Arcutis’ Board of Directors WESTLAKE VILLAGE, C...

Seven IPOs and one SPAC plan to raise $2.1 billion in the week ahead, led by tax software provider Vertex (VERX). A handful of companies could join the IPO calendar in the coming week, including leading mortgage lender Rocket Companies (RKT), cloud hosting service provider Rackspace (RXT), a...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Arcutis Biotherapeutics ( ARQT -1.9% ) has completed enrollment of Phase 2b trial evaluating ARQ-154 (topical roflumilast foam) as a potential treatment for scalp psoriasis. More news on: Arcutis Biotherapeutics, Inc., Healthcare stocks news, Read more ...

Roflumilast foam potential “Best in Class” topical PDE4 inhibitor in foam formulation Scalp psoriasis affects more than 2.5 million U.S. patients Phase 2b topline data anticipated fourth quarter 2020 WESTLAKE VILLAGE, Calif., July 20, 2020 (GLOBE NEWSWIRE) -- Arcutis Bi...

Data demonstrate potential “Best in Class” topical PDE4 inhibitor roflumilast significantly improves chronic plaque psoriasis Phase 3 topline data anticipated first half of 2021 WESTLAKE VILLAGE, Calif., July 15, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc . (N...

Arcutis Biotherapeutics ( ARQT -2.8% ) initiates enrollment in the Phase 2b portion of Phase 1/2b study  of ARQ-252, selective topical small molecule Janus kinase type 1 inhibitor, in chronic hand eczema. More news on: Arcutis Biotherapeutics, Inc., Healthcare...

ARQ-252 is a potent and highly selective topical JAK1 inhibitor offering potential safety advantages over less selective JAK inhibitors Company expects topline data in the second half of 2021 WESTLAKE VILLAGE, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc . (...